PHARMACOR ATORVASTATIN atorvastatin (as calcium trihydrate) 40 mg film-coated tablet blister pack

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Osta se nyt

Lataa Pakkausseloste (PIL)
23-12-2020
Lataa Valmisteyhteenveto (SPC)
16-09-2021

Aktiivinen ainesosa:

atorvastatin calcium trihydrate, Quantity: 43.38 mg (Equivalent: atorvastatin, Qty 40 mg)

Saatavilla:

Pharmacor Pty Ltd

INN (Kansainvälinen yleisnimi):

atorvastatin calcium trihydrate

Lääkemuoto:

Tablet, film coated

Koostumus:

Excipient Ingredients: polysorbate 80; hyprolose; lactose monohydrate; calcium carbonate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; purified talc

Antoreitti:

Oral

Kpl paketissa:

30's, 10's

Prescription tyyppi:

(S4) Prescription Only Medicine

Käyttöaiheet:

Atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. Atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see section 5.1, Pharmacodynamic properties, Prevention of Cardiovascular Disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Tuoteyhteenveto:

Visual Identification: White elliptical shaped, film coated tablets, debossed with "40" on one side and 'ATS' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Valtuutuksen tilan:

Licence status A

Valtuutus päivämäärä:

2017-09-11

Pakkausseloste

                                PHARMACOR ATORVASTATIN (Version-04) Page 1 of 5
PHARMACOR ATORVASTATIN
_ _
_Atorvastatin (as calcium trihydrate)_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some of the
more common questions about
Pharmacor Atorvastatin
It does not contain all of the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All
medicines
have
risks
and
benefits. Your doctor has weighed
the
risks
of
you
taking
Pharmacor
Atorvastatin
against
the
benefits
he/she expects it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT PHARMACOR
ATORVASTATIN IS USED FOR
Pharmacor
Atorvastatin
is
used
to
lower high cholesterol levels.
Pharmacor Atorvastatin is also used
to help reduce the risk of having a
heart attack or stroke in people who
have
high
blood
pressure
and
coronary heart disease (CHD) or who
are at risk of CHD. Examples of risk
factors for CHD include diabetes, a
history
of
stroke,
or
small
blood
vessel disease.
_WHAT IS CHOLESTEROL?_
Everyone
has
cholesterol
in
their
blood. It is a type of blood fat needed
by the body for many things, such as
building the cell lining, making bile
acids (which help to digest food) and
some hormones. However, too much
cholesterol can be a problem.
Cholesterol is present in many foods
and is also made in your body by the
liver. If your body makes too much
cholesterol
or
you
have
too
much
cholesterol in your diet, then your
level becomes too high.
High cholesterol is more likely to
occur with certain diseases or if you
have
a
family
history
of
high
cholesterol.
There
are
different
types
of
cholesterol.
LDL,
or
low-density
lipoprotein, is the 'bad' cholesterol
that can block your blood vessels.
HDL, or high density lipoprotein,
cholesterol is the 'good' cholesterol
that is thought to remove the bad
cholesterol from the blood vessels.
When you have high levels of 'bad'
cholesterol
in
your
blood,
it
may
begin to 'stic
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                PHARMACOR ATORVASTATIN (Version-06)
Page 1
AUSTRALIAN
PRODUCT
INFORMATION
-
PHARMACOR ATORVASTATIN (ATORVASTATIN (AS CALCIUM
TRIHYDRATE))
1.
NAME OF THE MEDICINE
atorvastatin (as calcium trihydrate)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
PHARMACOR ATORVASTATIN 10 MG
– Each tablets contains 10 mg atorvastatin (as
calcium trihydrate)
PHARMACOR ATORVASTATIN 20 MG
– Each tablets contains 20 mg atorvastatin (as
calcium trihydrate)
PHARMACOR ATORVASTATIN 40 MG
– Each tablets contains 40 mg atorvastatin (as
calcium trihydrate)
PHARMACOR ATORVASTATIN 80 MG
– Each tablets contains 80 mg atorvastatin (as
calcium trihydrate)
EXCIPIENTS WITH KNOWN EFFECT
– sugars as lactose monohydrate
For the full list of excipients, see
SECTION 6.1
,
LIST OF EXCIPIENTS
3.
PHARMACEUTICAL FORM
PHARMACOR ATORVASTATIN is supplied as White elliptical shaped film
coated tablets,
10, 20, 40 and 80 mg atorvastatin as atorvastatin calcium. Each tablet
is debossed with the
tablet strength on one side and ‘ATS’ on the other as follows:
10 mg: debossed ‘10’ on one side and ‘ATS’ on the other.
20 mg: debossed ‘20’ on one side and ‘ATS’ on the other.
40 mg: debossed ‘40’ on one side and ‘ATS’ on the other.
80 mg: debossed ‘80’ on one side and ‘ATS’ on the other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PHARMACOR ATORVASTATIN is indicated as an adjunct to diet for the
treatment of
patients with hypercholesterolaemia.
Prior to initiating therapy with atorvastatin, secondary causes of
hypercholesterolaemia (e.g.
poorly controlled diabetes mellitus, hypothyroidism, nephrotic
syndrome,
PHARMACOR ATORVASTATIN (Version-06)
Page 2
dysproteinaemias, obstructive liver disease, other drug therapy, and
alcoholism) should be
identified and treated.
PHARMACOR ATORVASTATIN is indicated in hypertensive patients with
multiple risk
factors for coronary heart disease (CHD) which may include diabetes,
history of stroke or
other cerebrovascular disease, peripheral vascular disease or existing
asymptomatic CHD (se
                                
                                Lue koko asiakirja